Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Cagrilintide represents a novel approach to obesity management
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Subscribe To Our Newsletter & Stay Updated
